Why the study?
Dual antiplatelet therapy with ASA and P2Y12 inhibitors is essential after acute coronary syndrome, but direct comparisons between newer agents prasugrel and ticagrelor are lacking.
This review summarizes the tailored use of dual antiplatelet therapy, highlighting the selection between clopidogrel, prasugrel, and ticagrelor based on patient comorbidities and clinical presentation in acute coronary syndrome.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Miklík et al. (2016) conducted a review in Acute coronary syndrome (ACS). Dual antiplatelet therapy (prasugrel, ticagrelor, clopidogrel) was evaluated.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: